LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

May 19, 2025

TR-1: Standard form for notification of major holdings

1. Issuer Details ISIN USU5500L1045 Issuer Name LungLife AI, Inc. UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Cable Car Capital LLC City of registered office (if applicable) San Francisco Country of registered office (if applicable) United […]
• Read More
April 29, 2025

Proposed cancellation of admission of Common Shares to trading on AIM; Proposed Stockholder approval of Exclusive License and Distribution Agreement And Notice of Special Meeting  

 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that, further to its previous announcements, the Company will shortly send a circular to Stockholders (the "Circular"), which contains a notice of Special Meeting of Stockholders (the “Special Meeting”) and resolutions (the “Resolutions”) in connection with the proposed cancellation of admission […]
• Read More
1 2 3 38
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down